IN2014DN05972A - - Google Patents

Info

Publication number
IN2014DN05972A
IN2014DN05972A IN5972DEN2014A IN2014DN05972A IN 2014DN05972 A IN2014DN05972 A IN 2014DN05972A IN 5972DEN2014 A IN5972DEN2014 A IN 5972DEN2014A IN 2014DN05972 A IN2014DN05972 A IN 2014DN05972A
Authority
IN
India
Prior art keywords
diseases associated
present
glucose metabolism
therapeutic agent
abnormal glucose
Prior art date
Application number
Inventor
Ichiro Hisatome
Shunsuke Tsujimoto
Takashi Shirakura
Shinya Hiramitsu
Original Assignee
Teijin Pharma Ltd
Nat Univ Corp Tottori Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd, Nat Univ Corp Tottori Univ filed Critical Teijin Pharma Ltd
Publication of IN2014DN05972A publication Critical patent/IN2014DN05972A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The purpose of the present invention is to provide a novel therapeutic agent or a novel prophylactic agent for diseases associated with abnormal glucose metabolism. The present invention is a therapeutic agent or a prophylactic agent for diseases associated with abnormal glucose metabolism which comprises a 2 phenylthiazole compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
IN5972DEN2014 2012-01-27 2013-01-25 IN2014DN05972A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012015351 2012-01-27
PCT/JP2013/051627 WO2013111870A1 (en) 2012-01-27 2013-01-25 Therapeutic agent for diabetes

Publications (1)

Publication Number Publication Date
IN2014DN05972A true IN2014DN05972A (en) 2015-06-26

Family

ID=48873581

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5972DEN2014 IN2014DN05972A (en) 2012-01-27 2013-01-25

Country Status (15)

Country Link
US (1) US20150005506A1 (en)
EP (1) EP2808018B1 (en)
JP (1) JP5924699B2 (en)
KR (1) KR20140134266A (en)
CN (1) CN104066430A (en)
AR (1) AR089812A1 (en)
AU (1) AU2013212865A1 (en)
BR (1) BR112014017902A2 (en)
CA (1) CA2862602A1 (en)
HK (1) HK1201209A1 (en)
IN (1) IN2014DN05972A (en)
MX (1) MX2014008484A (en)
RU (1) RU2014134845A (en)
TW (1) TW201334779A (en)
WO (1) WO2013111870A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104628671B (en) * 2015-02-10 2016-04-13 佛山市赛维斯医药科技有限公司 Containing oil of mirbane thiazole carboxylic acid amides compounds and the purposes of benzene carbon amidine structure
CN104610188B (en) * 2015-02-10 2016-07-27 佛山市赛维斯医药科技有限公司 Itrile group benzene thiazole carboxylic acid amides's compounds containing benzene carbon amidine structure, its preparation and purposes
CN104628673A (en) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 Nitrile benzene thiazolecarboxamide type compound containing tert-butylamidine structure and application thereof
CN104628672A (en) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 Alkoxyphenylthiazole carboxylic acid amide compounds containing phenylamidine structures and application
CN104610190B (en) * 2015-02-10 2016-08-17 佛山市赛维斯医药科技有限公司 One class contains halogenophenyl thiazole carboxylic acid amides's compounds and the purposes of cyclopropyl amidine structure
KR102473677B1 (en) * 2015-08-17 2022-12-02 삼성디스플레이 주식회사 Liquid crystal display
US11344539B2 (en) 2016-02-19 2022-05-31 National University Corporation Tottori University Therapeutic or prophylactic drug for dementia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122008000051I1 (en) 1990-11-30 2009-02-05 Teijin Ltd 2-ARYLTHIAZOL DERIVATIVE AND MEDICAMENT CONTAINING THEREOF
HUP9902721A2 (en) * 1997-11-25 1999-12-28 The Procter & Gamble Co. Concentrated fabric softening composition and highly unsaturated fabric softener compound therefor
US20050074442A1 (en) * 2002-03-13 2005-04-07 Natarajan Ranganathan Compositions and methods for augmenting kidney function
WO2006012438A2 (en) * 2004-07-21 2006-02-02 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of insulin resistance
CA2617161A1 (en) * 2005-07-21 2007-02-15 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of hyperuricemia related health consequences
JP5242393B2 (en) 2005-08-03 2013-07-24 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド How to treat hypertension
EP1957064A4 (en) * 2005-11-21 2010-01-06 Tap Pharmaceutical Prod Inc Treatment of qt interval prolongation and diseases associated therewith
JP2007210978A (en) * 2006-02-13 2007-08-23 Hiroshima Univ Glucose intolerance, type II diabetes, hyperlipidemia, metabolic syndrome, visceral fat obesity, fatty liver or non-alcoholic steatohepatitis
EP2101761A4 (en) 2006-11-13 2010-01-27 Takeda Pharmaceuticals North A Methods for preserving renal function using xanthine oxidoreductase inhibitors
BRPI0819847B1 (en) * 2007-11-27 2022-01-11 Ardea Biosciences, Inc COMPOUNDS AND COMPOSITIONS
US8394792B2 (en) * 2008-03-31 2013-03-12 C&C Research Laboratories Heterocyclic derivatives
MX2010011603A (en) * 2008-04-30 2011-01-25 Wellstat Therapeutics Corp Tetrazole compounds for reducing uric acid.
BRPI0913129A2 (en) * 2008-05-22 2016-01-05 Bristol Myers Squibb Co method for treating hyperuricemia employing an sglt2 inhibitor and composition containing the same
JP2012505925A (en) * 2008-10-19 2012-03-08 リチャード ジェイ ジョンソン Therapeutic compositions and methods for treating chronic kidney disease associated with metabolic imbalance
EP2470268A4 (en) * 2009-08-24 2012-12-26 Wound Man Pty Ltd DIAGNOSIS AND THERAPY OF WOUNDS TARGETING PURINES
US9248119B2 (en) * 2010-06-16 2016-02-02 Takeda Pharmaceuticals U.S.A., Inc. Modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
PH12012502487A1 (en) * 2010-06-25 2017-08-09 Teijin Pharma Ltd Sustained-release therapeutic agent for hypertension and renal dysfunction

Also Published As

Publication number Publication date
RU2014134845A (en) 2016-03-20
JPWO2013111870A1 (en) 2015-05-11
TW201334779A (en) 2013-09-01
US20150005506A1 (en) 2015-01-01
AU2013212865A1 (en) 2014-08-14
HK1201209A1 (en) 2015-08-28
CN104066430A (en) 2014-09-24
WO2013111870A1 (en) 2013-08-01
BR112014017902A2 (en) 2017-08-22
EP2808018A4 (en) 2015-07-15
KR20140134266A (en) 2014-11-21
EP2808018B1 (en) 2018-03-14
EP2808018A1 (en) 2014-12-03
MX2014008484A (en) 2014-10-14
AR089812A1 (en) 2014-09-17
CA2862602A1 (en) 2013-08-01
JP5924699B2 (en) 2016-05-25

Similar Documents

Publication Publication Date Title
MX2015003594A (en) Therapeutic or prophylactic agent for tumor lysis syndrome.
IN2015MN00404A (en)
MY183312A (en) Pharmaceutical formulation
AU2012214029A8 (en) Rorgammat inhibitors
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2015017861A (en) Benzothiophene derivatives as estrogen receptor inhibitors.
PH12015502839B1 (en) Antiviral compounds
MX2015005286A (en) Process for preparing bile acid derivatives.
PH12017501429A1 (en) Derivatives of betulin
IN2015DN00185A (en)
MX2015010971A (en) Novel pyrazole derivative.
JO3530B1 (en) 1,4-disubstituted pyridazine analogs there of and methods for treating smn-deficiency-related conditions
IN2014MN02106A (en)
AU2012321815A8 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
MY187718A (en) Pharmaceutical formulations
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
PH12015501752B1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
MX364400B (en) Tetracycline compounds.
WO2011159124A3 (en) Novel benzoxazole derivative having inhibitory activity against interleukin-6, preparation method thereof, and pharmaceutical composition containing same
PH12014500065A1 (en) A new therapeutical composition containing apomorphine as active ingredient
WO2011123536A8 (en) Polycyclic tetracycline compounds
NZ711343A (en) Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation
IN2014CN04449A (en)
MY173491A (en) Therapeutic or prophylactic agent for biliary tract diseases
MX362919B (en) Bicyclo [2.2.1] acid gpr120 modulators.